AUTOLOGOUS MATRIX-INDUCED CHONDROGENESIS MARKET ANALYSIS

Autologous Matrix-induced Chondrogenesis Market, by Material Type (Collagen, Polyethylene Glycol, Polylactic-Co-Glycolic Acid, and Hyaluronic Acid), by Application (Knee Cartilage, Elbow Cartilage, and Hip Cartilage), by Region (North America, Latin America, Europe, Asia Pacific, Middle East, And Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022-2028

To Be Published : Dec 2024
Code : CMI2748
Formats :
Excel and PDF
Industry : Biotechnology

Autologous Matrix-induced Chondrogenesis MarketSize and Trends

Autologous matrix-induced chondrogenesis is an innovative treatment to repair articular cartilage damage. It is a one step process that uses the microfracturing method, which is followed by application of bilayer collagen I/III membrane by partially autologous fibrin glue. Increasing prevalence of bone and joint disorders such as osteoporosis and arthritis, increasing sports-related injuries, and rising demand for minimally-invasive surgery is driving the autologous matrix-induced chondrogenesis market growth.

Autologous Matrix-induced Chondrogenesis Market - Market Trends

Increasing number of joint and bone disorders such as osteoporosis and arthritis globally is expected to drive the autologous matrix-induced chondrogenesis market growth during the forecast period. For instance, according to the National Center for Biotechnology Information (NCBI) 2016 report, over 200 million people are suffering from osteoporosis worldwide in 2015. 1 in 3 women over the age of 50 years and 1 in 5 men will experience osteoporosis fractures in their lifetime.

Rising number of surgeries is expected to drive the autologous matrix-induced chondrogenesis market growth during the forecast period. For instance, according to American Academy of Orthopaedic Surgeon (AAOS) 2019 report, around 267,000 knee replacements are performed each year in the U.S.